Agios Pharmaceuticals Statistics

Total Valuation

FRA:8AP has a market cap or net worth of EUR 1.45 billion. The enterprise value is 500.44 million.

Market Cap	1.45B
Enterprise Value	500.44M

Important Dates

The last earnings date was Thursday, February 12, 2026.

Earnings Date	Feb 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	58.59M
Shares Outstanding	n/a
Shares Change (YoY)	+0.14%
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	49.38M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	31.61
PB Ratio	1.43
P/TBV Ratio	1.43
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.42
EV / Sales	10.91
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.56

Financial Position

The company has a current ratio of 11.46, with a Debt / Equity ratio of 0.03.

Current Ratio	11.46
Quick Ratio	10.52
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.11
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -30.20% and return on invested capital (ROIC) is -125.09%.

Return on Equity (ROE)	-30.20%
Return on Assets (ROA)	-19.94%
Return on Invested Capital (ROIC)	-125.09%
Return on Capital Employed (ROCE)	-38.86%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	85,214
Profits Per Employee	-651,047
Employee Count	540
Asset Turnover	0.04
Inventory Turnover	11.43

Taxes

Income Tax	-865,327
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -23.90% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-23.90%
50-Day Moving Average	23.16
200-Day Moving Average	29.04
Relative Strength Index (RSI)	57.25
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.32

Income Statement

In the last 12 months, FRA:8AP had revenue of EUR 46.02 million and -351.57 million in losses. Loss per share was -6.06.

Revenue	46.02M
Gross Profit	-248.57M
Operating Income	-402.11M
Pretax Income	-352.43M
Net Income	-351.57M
EBITDA	-397.71M
EBIT	-402.11M
Loss Per Share	-6.06

Full Income Statement

Balance Sheet

The company has 727.71 million in cash and 34.24 million in debt, with a net cash position of 957.51 million.

Cash & Cash Equivalents	727.71M
Total Debt	34.24M
Net Cash	957.51M
Net Cash Per Share	n/a
Equity (Book Value)	1.02B
Book Value Per Share	17.39
Working Capital	732.33M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -317.66 million and capital expenditures -3.68 million, giving a free cash flow of -321.34 million.

Operating Cash Flow	-317.66M
Capital Expenditures	-3.68M
Free Cash Flow	-321.34M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-873.87%
Pretax Margin	-765.89%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:8AP does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.14%
Shareholder Yield	-0.14%
Earnings Yield	-24.17%
FCF Yield	-22.09%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:8AP has an Altman Z-Score of 10.39 and a Piotroski F-Score of 3.

Altman Z-Score	10.39
Piotroski F-Score	3